Effects of nanophase materials (≤20 nm) on biological responsesCHENG, Meng-Dawn.Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering. 2004, Vol 39, Num 10, pp 2691-2705, 15 p.Article

Side effects of the biologicsHEYMANN, Warren R; WOLVERTON, Stephen E; BRAUNEIR, Gary et al.Journal of the American Academy of Dermatology. 2005, Vol 53, Num 4, pp 692-693, issn 0190-9622, 2 p.Article

Induction of interferons and interferon-induced genesSAMUEL, C. E; OZATO, K.Biotherapy (Dordrecht). 1996, Vol 8, Num 3-4, pp 183-187, issn 0921-299XArticle

Biological Therapy of CancerJournal of immunotherapy (1997). 2009, Vol 32, Num 9, pp 941-1012, issn 1524-9557, 72 p.Conference Paper

Biological Therapy and Other Novel Therapies in Early-Stage Disease : Are They Appropriate?GROTHEY, Axel.Clinical cancer research. 2007, Vol 13, Num 22, issn 1078-0432, 6909s-6912sConference Paper

The probiotic paradox: live and dead cells are biological response modifiersADAMS, Clifford A.Nutrition research reviews. 2010, Vol 23, Num 1, pp 37-46, issn 0954-4224, 10 p.Article

Annual Scientific Meeting of the International Society for Biological Therapy of CancerJournal of immunotherapy (1997). 2010, Vol 33, Num 8, pp 859-920, issn 1524-9557, 62 p.Conference Paper

Enhancing effects of new biological response modifier β-1,3 glucan sulfate PS3 on immune reactions : Present status of drug from marine originVETVICKA, Vaclav; VETVICKOVA, Jana; FRANK, Jamois et al.Biomedicine & pharmacotherapy. 2008, Vol 62, Num 5, pp 283-288, issn 0753-3322, 6 p.Article

Annual Scientific Meeting of the International Society for Biological Therapy of CancerJournal of immunotherapy (1997). 2007, Vol 30, Num 8, pp 855-904, issn 1524-9557, 49 p.Conference Paper

Interferon receptorsLANGER, J; GAROTTA, G; PESTKA, S et al.Biotherapy (Dordrecht). 1996, Vol 8, Num 3-4, pp 163-174, issn 0921-299XArticle

Combination immunosuppressive therapies : The promise and the perilROBINSON, Maria R; KORMAN, Benjamin D; KORMAN, Neil J et al.Archives of dermatology (1960). 2007, Vol 143, Num 8, pp 1053-1057, issn 0003-987X, 5 p.Article

Cytokine-mediated biological response to severe infections in surgical patientsAIKAWA, N; FUJISHIMA, S; SHINOZAWA, Y et al.Nippon Geka Gakkai Zasshi. 1996, Vol 97, Num 12, pp 1054-1059, issn 0301-4894Article

Type I interferon genes and proteinsDIAZ, M. O; TESTA, D.Biotherapy (Dordrecht). 1996, Vol 8, Num 3-4, pp 157-162, issn 0921-299XArticle

Factors inhibiting IFN activitySCHELLEKENS, H; VAN DER MEIDE, P. H; VON WUSSOW, P et al.Biotherapy (Dordrecht). 1996, Vol 8, Num 3-4, pp 199-204, issn 0921-299XArticle

Quantification of the SLAMENGHI factors for carotenoid bioavailability and bioconversionWEST, C. E; CASTENMILLER, J. J. J. M.International journal for vitamin and nutrition research. 1998, Vol 68, Num 6, pp 371-377, issn 0300-9831Conference Paper

Biological response modifier therapy for refractory childhood uveitisGALLAGHER, Michael; QUINONES, Karina; CERVANTES-CASTANEDA, Rene Antonio et al.British journal of ophthalmology. 2007, Vol 91, Num 10, pp 1341-1344, issn 0007-1161, 4 p.Article

Biologics in psoriasis : A quick reference guideTHOMAS, Valencia D; YANG, F. Clarissa; KVEDAR, Iosenh C et al.Journal of the American Academy of Dermatology. 2005, Vol 53, Num 2, pp 346-351, issn 0190-9622, 6 p.Article

Evaluation of the purity of levamisole hydrochloride by differential scanning calorimetryDHANESAR, S. C.American laboratory (Fairfield). 1998, Vol 30, Num 14, pp 48-50, issn 0044-7749Article

Innate immunity and cancer therapyMARUYAMA, Kouji; SELMANI, Zohair; ISHII, Hidee et al.International immunopharmacology (Print). 2011, Vol 11, Num 3, pp 350-357, issn 1567-5769, 8 p.Article

Combination of biological therapies in non-small cell lung cancerBIANCO, R; DAMIANO, V; TORTORA, G et al.Annals of oncology. 2006, Vol 17, issn 0923-7534, ii52-ii54, SUP2Conference Paper

Traitements biologiques du psoriasis : nature et mécanismes d'action = Psoriasis biological treatments: nature and mode of action. Summary : Putting an end to a long period without significantJULLIEN, D.Les Nouvelles dermatologiques. 2005, Vol 24, Num 6, pp 361-367, issn 0752-5370, 7 p., CAH1Article

Psoriasis et anti-TNFα : nouvelles stratégies thérapeutiques = Psoriasis and anti-TNFα: new therapeutic strategiesAnnales de dermatologie et de vénéréologie. 2005, Vol 132, Num 8-9, issn 0151-9638, 12 p., CAH2Serial Issue

The patient advocate perspective on preparing for fda advisory committee presentationsMEYERS, Abbey S.Drug information journal. 2000, Vol 34, Num 3, pp 969-973, issn 0092-8615Article

Natural and therapeutically-induced antibodies to cytokinesREVOLTELLA, R. P.Biotherapy (Dordrecht). 1998, Vol 10, Num 4, pp 321-331, issn 0921-299XArticle

Combination therapy with brms in cancer and infectious diseasesGARACI, E; PICA, F; RASI, G et al.Mechanisms of ageing and development. 1997, Vol 96, Num 1-3, pp 103-116, issn 0047-6374Conference Paper